Terms: = Lung cancer AND MAP2K1, MAPKK1, 5604, ENSG00000169032, Q02750, MEK1, MKK1, PRKMK1 AND Treatment
160 results:
1. Gefitinib Induces Apoptosis in NSCLC Cells by Promoting Glutaminolysis and Inhibiting the MEK/ERK Signaling Pathway.
Zhang Y; Liu H; Liu X; Lang L
Discov Med; 2024 Apr; 36(183):836-841. PubMed ID: 38665031
[TBL] [Abstract] [Full Text] [Related]
2. Tet methylcytosine dioxygenase 2 (TET2) deficiency elicits EGFR-TKI (tyrosine kinase inhibitors) resistance in non-small cell lung cancer.
Zhang J; Zhao K; Zhou W; Kang R; Wei S; Shu Y; Yu C; Ku Y; Mao Y; Luo H; Yang J; Mei J; Pu Q; Deng S; Zha Z; Yuan G; Shen S; Chen Y; Liu L
Signal Transduct Target Ther; 2024 Mar; 9(1):65. PubMed ID: 38461173
[TBL] [Abstract] [Full Text] [Related]
3. Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update.
Roskoski R
Pharmacol Res; 2024 Feb; 200():107059. PubMed ID: 38216005
[TBL] [Abstract] [Full Text] [Related]
4. Identification of Bulbocodin D and C as novel STAT3 inhibitors and their anticancer activities in lung cancer cells.
He X; Fu J; Lyu W; Huang M; Mo J; Cheng Y; Xu Y; Zheng L; Zhang X; Qi L; Zhang L; Zheng Y; Huang M; Ni L; Lu J
Chin J Nat Med; 2023 Nov; 21(11):842-851. PubMed ID: 38035939
[TBL] [Abstract] [Full Text] [Related]
5. Selumetinib overcomes gefitinib primary and acquired resistance by regulating MIG6/STAT3 in NSCLC.
Song X; Wang L; Tang W; Yuan L; Liu Q; Li J; Fan D
Arch Pharm Res; 2023 Dec; 46(11-12):924-938. PubMed ID: 38032449
[TBL] [Abstract] [Full Text] [Related]
6. Multi-gene Liquid Biopsy to Detect Resistance to First-line Osimertinib in Patients With
Ito S; Tsurumi K; Shindo N; Soma S; Yamaguchi K; Tamai K; Mochizuki M; Fujimori H; Morita M; Watanabe K; Suzuki A; Fukuhara T; Yasuda J
Anticancer Res; 2023 Nov; 43(11):5031-5040. PubMed ID: 37909987
[TBL] [Abstract] [Full Text] [Related]
7. Pulmonary Langerhans cell histiocytosis - an update on pathogenesis and treatment.
Jouenne F; Benattia A; Tazi A
Curr Opin Pulm Med; 2023 Sep; 29(5):451-458. PubMed ID: 37410483
[TBL] [Abstract] [Full Text] [Related]
8. Resistance to KRAS G12C Inhibition in Non-small Cell lung cancer.
Di Federico A; Ricciotti I; Favorito V; Michelina SV; Scaparone P; Metro G; De Giglio A; Pecci F; Lamberti G; Ambrogio C; Ricciuti B
Curr Oncol Rep; 2023 Sep; 25(9):1017-1029. PubMed ID: 37378881
[TBL] [Abstract] [Full Text] [Related]
9. Trametinib in Patients With
Wisinski KB; Flamand Y; Wilson MA; Luke JJ; Tawbi HA; Hong F; Mitchell EP; Zwiebel JA; Chen H; Gray RJ; Li S; McShane LM; Rubinstein LV; Patton D; Williams PM; Hamilton SR; Behrens RJ; Pennington KP; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT
JCO Precis Oncol; 2023 Apr; 7():e2200421. PubMed ID: 37053535
[TBL] [Abstract] [Full Text] [Related]
10. The heterogeneous transition state of resistance to RET kinase inhibitors converges on ERK1/2-driven Aurora A/B kinases.
Hu X; Liu X; Khatri U; Wu J
Drug Resist Updat; 2023 May; 68():100958. PubMed ID: 36990046
[TBL] [Abstract] [Full Text] [Related]
11. Combination of the LARS1 Inhibitor, BC-LI-0186 with a mek1/2 Inhibitor Enhances the Anti-Tumor Effect in Non-Small Cell lung cancer.
Lee SH; Kim EY; Han JM; Han G; Chang YS
Cancer Res Treat; 2023 Jul; 55(3):851-864. PubMed ID: 36960627
[TBL] [Abstract] [Full Text] [Related]
12. Comprehensive characterization of B7 family members in NSCLC and identification of its regulatory network.
Xiao M; Pang C; Xiang S; Zhao Y; Wu X; Li M; Du F; Chen Y; Wang F; Wen Q; Xiao Z; Yang Z; Shen J
Sci Rep; 2023 Mar; 13(1):4311. PubMed ID: 36922519
[TBL] [Abstract] [Full Text] [Related]
13. Multi-Omics Immune Interaction Networks in lung cancer Tumorigenesis, Proliferation, and Survival.
Ye Q; Hickey J; Summers K; Falatovich B; Gencheva M; Eubank TD; Ivanov AV; Guo NL
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499305
[TBL] [Abstract] [Full Text] [Related]
14. Properties of FDA-approved small molecule protein kinase inhibitors: A 2023 update.
Roskoski R
Pharmacol Res; 2023 Jan; 187():106552. PubMed ID: 36403719
[TBL] [Abstract] [Full Text] [Related]
15. Semi-Supervised Adversarial Learning for Improving the Diagnosis of Pulmonary Nodules.
Fu Y; Xue P; Xiao T; Zhang Z; Zhang Y; Dong E
IEEE J Biomed Health Inform; 2023 Jan; 27(1):109-120. PubMed ID: 36269913
[TBL] [Abstract] [Full Text] [Related]
16. Costunolide is a dual inhibitor of mek1 and AKT1/2 that overcomes osimertinib resistance in lung cancer.
Tian X; Wang R; Gu T; Ma F; Laster KV; Li X; Liu K; Lee MH; Dong Z
Mol Cancer; 2022 Oct; 21(1):193. PubMed ID: 36203195
[TBL] [Abstract] [Full Text] [Related]
17. Analysis of Circulating Tumor and cancer Stem Cells Provides New Opportunities in Diagnosis and treatment of Small Cell lung cancer.
Skurikhin EG; Ermakova N; Zhukova M; Pershina O; Pan E; Pakhomova A; Kogai L; Goldberg V; Simolina E; Skurikhina V; Widera D; Kubatiev A; Morozov SG; Kushlinskii N; Dygai A
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142766
[TBL] [Abstract] [Full Text] [Related]
18. CRISPR/Cas9-based genome-wide screening for deubiquitinase subfamily identifies USP1 regulating MAST1-driven cisplatin-resistance in cancer cells.
Tyagi A; Kaushal K; Chandrasekaran AP; Sarodaya N; Das S; Park CH; Hong SH; Kim KS; Ramakrishna S
Theranostics; 2022; 12(13):5949-5970. PubMed ID: 35966591
[No Abstract] [Full Text] [Related]
19. Identification of cell type-specific correlations between ERK activity and cell viability upon treatment with ERK1/2 inhibitors.
Lebedev TD; Khabusheva ER; Mareeva SR; Ivanenko KA; Morozov AV; Spirin PV; Rubtsov PM; Snezhkina AV; Kudryavtseva AV; Sorokin MI; Buzdin AA; Prassolov VS
J Biol Chem; 2022 Aug; 298(8):102226. PubMed ID: 35787369
[TBL] [Abstract] [Full Text] [Related]
20. Genetic determinants of lung cancer: Understanding the oncogenic potential of somatic missense mutations.
Dhakar R; Dakal TC; Sharma A
Genomics; 2022 Jul; 114(4):110401. PubMed ID: 35709927
[TBL] [Abstract] [Full Text] [Related]
[Next]